RS51331B - Upotreba pipamperona i antagonista d2-receptora ili serotoninsko/dopaminskih antagonista za lečenje psihotičkih poremećaja - Google Patents
Upotreba pipamperona i antagonista d2-receptora ili serotoninsko/dopaminskih antagonista za lečenje psihotičkih poremećajaInfo
- Publication number
- RS51331B RS51331B RSP-2010/0323A RSP20100323A RS51331B RS 51331 B RS51331 B RS 51331B RS P20100323 A RSP20100323 A RS P20100323A RS 51331 B RS51331 B RS 51331B
- Authority
- RS
- Serbia
- Prior art keywords
- antagonist
- pipamperone
- receptor antagonist
- psychotic disorders
- dopamin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Upoterba pipamperona ili njegove farmaceutski prihvatljive soli za proizvodnju leka za tečenje psihotičkih poremećaja, naznačena time što pipamperon ili navedena njegova farmaceutski prihvatljiva so treba da bude primenjena istovremeno sa, odvojeno od ili pre primenjivanja jedinjenja antagonista D2 receptora da bi se povećao terapeutski efekat ili da bi se ubrzao početak terapijskog dejstva navedenog jedinjenja antagonista D2 receptora, dalje naznačena time što pipamperon treba primeniti pacijentu u dnevnoj dozi, koja se kreće između 5 i 15 mg aktivnog sastojka.Prijava sadrži još 8 zavisnih patentnih zahteva.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03447279A EP1547650A1 (en) | 2003-12-02 | 2003-12-02 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
CA2451798A CA2451798C (en) | 2003-12-02 | 2003-12-02 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
US10/725,965 US7884096B2 (en) | 2003-12-02 | 2003-12-02 | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
EP04447001 | 2004-01-05 | ||
US10/752,423 US7855195B2 (en) | 2003-12-02 | 2004-01-06 | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
CA 2461248 CA2461248C (en) | 2003-12-02 | 2004-03-18 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
EP04447066A EP1576985A1 (en) | 2004-03-18 | 2004-03-18 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US10/803,793 US20050119249A1 (en) | 2003-12-02 | 2004-03-18 | Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
EP04025035A EP1541197B8 (en) | 2003-12-02 | 2004-10-21 | Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders |
JP2004349085A JP4571485B2 (ja) | 2003-12-02 | 2004-11-04 | D4および5−ht2aアンタゴニスト、逆アゴニストまたは部分アゴニストの使用 |
US10/984,683 US20050203130A1 (en) | 2003-12-02 | 2004-11-09 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
CA 2487529 CA2487529A1 (en) | 2003-12-02 | 2004-11-15 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
RS51331B true RS51331B (sr) | 2011-02-28 |
Family
ID=42134278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RSP-2010/0323A RS51331B (sr) | 2003-12-02 | 2004-12-02 | Upotreba pipamperona i antagonista d2-receptora ili serotoninsko/dopaminskih antagonista za lečenje psihotičkih poremećaja |
Country Status (8)
Country | Link |
---|---|
AT (1) | ATE464901T1 (sr) |
DE (1) | DE602004026781D1 (sr) |
DK (1) | DK1708790T3 (sr) |
ES (1) | ES2343962T3 (sr) |
HR (1) | HRP20100376T1 (sr) |
PT (1) | PT1708790E (sr) |
RS (1) | RS51331B (sr) |
SI (1) | SI1708790T1 (sr) |
-
2004
- 2004-12-02 AT AT04801138T patent/ATE464901T1/de active
- 2004-12-02 PT PT04801138T patent/PT1708790E/pt unknown
- 2004-12-02 DK DK04801138.1T patent/DK1708790T3/da active
- 2004-12-02 ES ES04801138T patent/ES2343962T3/es active Active
- 2004-12-02 RS RSP-2010/0323A patent/RS51331B/sr unknown
- 2004-12-02 SI SI200431439T patent/SI1708790T1/sl unknown
- 2004-12-02 DE DE602004026781T patent/DE602004026781D1/de active Active
-
2010
- 2010-07-06 HR HR20100376T patent/HRP20100376T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
DK1708790T3 (da) | 2010-06-21 |
DE602004026781D1 (de) | 2010-06-02 |
ATE464901T1 (de) | 2010-05-15 |
ES2343962T3 (es) | 2010-08-13 |
PT1708790E (pt) | 2010-07-09 |
SI1708790T1 (sl) | 2010-09-30 |
HRP20100376T1 (hr) | 2010-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
HRP20050077B1 (hr) | Postupci i oblici doziranja za kontrolirano oslobađanje paliperidona | |
NO20061859L (no) | OROS Push Stick for kontrollert tilforsel av aktive midler | |
ATE350040T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
JP2005515966A5 (sr) | ||
GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
RS53591B1 (sr) | Farmaceutske kompozicije za tretman poremećaja unutrašnjeg uva | |
DK1623703T3 (da) | Hydrocodonformuleringer med kontrolleret frigivelse | |
EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
TW200806318A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
RS54050B1 (sr) | Formulacije i metode za lečenje amiloidoze | |
CU23468B7 (es) | Forma de dosificación de pramipexol en una dosis única diaria | |
CA2661759A1 (en) | Buprenophine-wafer for drug substitution therapy | |
RS52256B (sr) | Terapeutske upotrebe jedinjenja sa kombinovanim sert, 5-ht3 i 5-ht1a aktivnostima | |
AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
WO2005055921A3 (en) | Compositions for treatment of ear disorders and methods of use thereof | |
SE0002754D0 (sv) | New pharmaceutical combination formulation and method of treatment with the combination | |
NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
NO20080244L (no) | Doseringsstyring for prasugrel | |
AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
WO2004037207A3 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | |
PL404315A1 (pl) | Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku | |
WO2007086079A3 (en) | Sustained release dosage form of phenothiazine derivatives containing channelizer | |
JP2016505050A5 (sr) |